03 August, 2017
Shire PLC (SHP) surged in London on Thursday, Aug. 3, after it posted a solid earnings beat for the second quarter and said it is ahead of schedule to meet its target for synergies following the acquisition of Baxalta. They now have a GBX 4,900 ($64.64) price objective on the biopharmaceutical company's stock. Citigroup Inc. reiterated a "buy" rating on shares of Shire PLC in a research note on Wednesday, April 12th. Inc. boosted its position in Shire PLC by 3.1% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company's stock worth $268,773,000 after buying an additional 13,665 shares during the last quarter. Laurion Capital Management LP bought a new stake in shares of Shire PLC during the first quarter valued at about $10,611,000. The company had a trading volume of 2,327,094 shares. HPM Partners LLC bought a new stake in Shire PLC during the first quarter valued at approximately $1,534,000.
Media headlines about Shire PLC (NASDAQ:SHPG) have been trending somewhat positive this week, according to Accern. Shire PLC has a 52-week low of $158.54 and a 52-week high of $209.22. The stock has a market capitalization of $49.77 billion, a P/E ratio of 171.38 and a beta of 1.60. "We have updated our 2017 full year guidance and remain very confident about Shire's long-term prospects".
Shire, which is based in Ireland but generates most of its sales in the United States, had second-quarter revenue of $3.75 billion and non-GAAP earnings of $3.73 per ADS (American Depositary Share), up 11 percent and above the consensus $3.60. The company had revenue of $3.57 billion for the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. During the same period past year, the business posted $2.12 EPS.
Shire, which reported 7 per cent growth in second-quarter product sales, said it expected to complete a strategic review of its Neuroscience franchise by the end of the year. Analysts anticipate that Shire PLC will post $14.84 EPS for the current year.
"The critical strategic decision before us is to determine how best to manage and operate these two businesses in a way that ensures that each has the appropriate level of management focus, investment and strategic flexibility", Ornskov said.
COPYRIGHT VIOLATION WARNING: This story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & worldwide copyright and trademark law.
SHPG has been the subject of a number of research reports. (The) reiterated a "buy" rating and issued a GBX 6,800 ($89.70) price target on shares of Shire PLC in a research note on Wednesday, April 12th. Finally, ValuEngine lowered shares of Shire PLC from a "buy" rating to a "hold" rating in a research report on Friday, June 2nd.
Shire PLC (LON:SHP)'s stock had its "hold" rating reiterated by analysts at Liberum Capital in a report issued on Thursday. Six brokerages rating the company a strong buy, sixteen brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of 73.73GBX.
Shire Pharma PLC (LON:SHP) said it is mulling a separate listing for its neuroscience franchise as it revealed the cost savings from the US$32bn takeover of United States rival Baxalta were now ahead of forecast. The stock presently has an average rating of "Buy" and a consensus price target of $223.64.
